Radiopharmaceutical developer Neoprobe plans to change its name to Navidea Biopharmaceuticals and to begin trading under a new ticker symbol on the NYSE Amex exchange on January 5, 2012.
In connection with the sale of Neoprobe's medical device business to Devicor Medical Products in August, the company began a corporate rebranding initiative to reflect its new focus in precision diagnostics. Navidea was chosen as the new name to reflect the company's dedication to "NAVigating IDEAs."
The firm plans to reveal a more complete view of the Navidea brand and an updated website in January in connection with the legal change to its corporate name. It will trade under the ticker symbol NAVB.
